ArticleJournal of neuro-oncology2025
Clinical, toxicity and long-term neurocognitive outcomes of first-line intensive chemotherapy in infant medulloblastoma: a single-center cohort study following AIEOP recommendations.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe long-term neurocognitive impact of craniospinal irradiation (CSI) in young children with medulloblastoma (MB) has driven the development of alternative strategies aimed at improving survival while delaying or avoiding CSI.
methodsWe retrospectively analyzed a cohort of patients under 5 years of age with MB treated at Bambino Gesù Children's Hospital between 2007 and 2023 with intensive chemotherapy regimens according to AIEOP recommendation. Clinical, radiological, histopathological, molecular, neurocognitive, and toxicity data were collected.
resultsAmong 42 patients under 5 years, 25 met inclusion criteria (median age 25.3 months, range 5.0-51.3). Histology included classic (52%), desmoplastic/nodular (20%), extensive nodularity (16%), and large cell/anaplastic (12%). SHH was the most common molecular subgroup (52%), followed by Group 3 (32%) and Group 4 (16%). At a median follow-up of 95.7 months, 68% were alive in complete remission. Two- and 5-year overall survival (OS) were 80.0% (95%CI: 58.4-91.1) and 65.9% (95%CI: 42.8-81.4); progression-free survival (PFS) was 68.0% (95%CI: 46.1-82.5) and 63.8% (95%CI: 41.8-79.2). Survival differed by risk group: low-risk patients achieved 100% OS and PFS, standard-risk intermediate, high-risk lowest. All experienced grade 3-4 hematological toxicity; late endocrine effects occurred in four patients, no other long-term toxicities reported. median IQ was stable from diagnosis (885.3) to last follow-up (8392.5.4).
conclusionOur retrospective study of infants MB treated with first-line intensive chemotherapy shows encouraging survival rates. Importantly, neurocognitive function was preserved over time, supporting radiation-sparing strategies, and toxicity was manageable in all cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.